By Henry Ehrlich
As to the all-important pricing questions, which I raised at the recent “summit” I received the following from a Sanofi spokesperson: “Also, per our discussions and your questions, we have set the price of Auvi-Q at the same list price as EpiPen. However, as I am sure you are aware, the final price an individual consumer pays for Auvi-Q is not determined by Sanofi.”
So let the games begin. Clearly price will not be the critical selling point, at least right away. Sanofi is betting that its product will win market share on the basis of other features. Let’s hope that competition will work the way it’s supposed to, with a better medical deal for patients.